Neuronal apoptosis linked to EgIN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental culling and cancer

被引:414
作者
Lee, S
Nakamura, E
Yang, HF
Wei, WY
Linggi, MS
Sajan, MP
Farese, RV
Freeman, RS
Carter, BD
Kaelin, WG [1 ]
Schlisio, S
机构
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Mol Oncol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA
[3] Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA
[4] James A Haley Vet Hosp, Dept Internal Med, Tampa, FL 33612 USA
[5] Univ S Florida, Coll Med, Tampa, FL 33612 USA
[6] Univ Rochester, Dept Physiol & Pharmacol, Rochester, NY 14642 USA
[7] Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Nashville, TN 37232 USA
[8] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA
关键词
D O I
10.1016/j.ccr.2005.06.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Germline NF1, c-RET, SDH, and VHL mutations cause familial pheochromocytoma. Pheochromocytomas derive from sympathetic neuronal precursor cells. Many of these cells undergo c-Jun-dependent apoptosis during normal development as NGF becomes limiting. NF1 encodes a GAP for the NGF receptor TrkA, and NF1 mutations promote survival after NGF withdrawal. We found that pheochromocytoma-associated c-RET and VHL mutations lead to increased JunB, which blunts neuronal apoptosis after NGF withdrawal. We also found that the prolyl hydroxylase EgIN3 acts downstream of c-Jun and is specifically required among the three EgIN family members for apoptosis in this setting. Moreover, EgIN3 proapoptotic activity requires SDH activity because EgIN3 is feedback inhibited by succinate. These studies suggest that failure of developmental apoptosis plays a role in pheochromocytoma pathogenesis.
引用
收藏
页码:155 / 167
页数:13
相关论文
共 79 条
  • [1] Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor
    Appelhoff, RJ
    Tian, YM
    Raval, RR
    Turley, H
    Harris, AL
    Pugh, CW
    Ratcliffe, PJ
    Gleadle, JM
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (37) : 38458 - 38465
  • [2] Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors
    Aprelikova, O
    Chandramouli, GVR
    Wood, M
    Vasselli, JR
    Riss, J
    Maranchie, JK
    Linehan, WM
    Barrett, JC
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2004, 92 (03) : 491 - 501
  • [3] Aravind L., 2001, GENOME BIOL, V2, p7.1
  • [4] HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia
    Berra, E
    Benizri, E
    Ginouvès, A
    Volmat, V
    Roux, D
    Pouysségur, J
    [J]. EMBO JOURNAL, 2003, 22 (16) : 4082 - 4090
  • [5] A conserved family of prolyl-4-hydroxylases that modify HIF
    Bruick, RK
    McKnight, SL
    [J]. SCIENCE, 2001, 294 (5545) : 1337 - 1340
  • [6] Pheochromocytoma: The expanding genetic differential diagnosis
    Bryant, J
    Farmer, J
    Kessler, LJ
    Townsend, RR
    Nathanson, KL
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (16) : 1196 - 1204
  • [7] Direct transactivation of the anti-apoptotic gene apolipoprotein J (Clusterin) by B-MYB
    Cervellera, M
    Raschella, G
    Santilli, G
    Tanno, B
    Ventura, A
    Mancini, C
    Sevignani, C
    Calabretta, B
    Sala, A
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (28) : 21055 - 21060
  • [8] Differential regulation of HIF-1α prolyl-4-hydroxylase genes by hypoxia in human cardiovascular cells
    Cioffi, CL
    Liu, XQ
    Kosinski, PA
    Garay, M
    Bowen, BR
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 303 (03) : 947 - 953
  • [9] Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease
    Clifford, SC
    Cockman, ME
    Smallwood, AC
    Mole, DR
    Woodward, ER
    Maxwell, PH
    Ratcliffe, PJ
    Maher, ER
    [J]. HUMAN MOLECULAR GENETICS, 2001, 10 (10) : 1029 - 1038
  • [10] von Hippel-Lindau tumor suppressor: not only HIF's executioner
    Czyzyk-Krzeska, MF
    Meller, J
    [J]. TRENDS IN MOLECULAR MEDICINE, 2004, 10 (04) : 146 - 149